Showing 2511-2520 of 3380 results for "".
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- MELA Sciences Rings in Melanoma Monday with NASDAQ Opening Bellhttps://practicaldermatology.com/news/20120507-mela_sciences_rings_in_melanoma_monday_with_nasdaq_opening_bell/2459807/MELA Sciences, Inc. (NASDAQ: MELA) is kicking off Melanoma/Skin Cancer Detection and Prevention Month by ringing the opening bell for NASDAQ Monday morning. Dr. Doris Day will ring
- Promiseb Complete Launches for Seborrheic Dermatitishttps://practicaldermatology.com/news/20120425-promiseb_complete_launches_for_seborrheic_dermatitis/2459814/Promiseb Complete, a new regimen for patients with seborrheic dermatitis (SD), is now available from Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories,. The line features Promiseb Topical Cream, a non-steroidal, prescription cream fo
- Hydrocolloid Dressings After Mohs Surgery Yield No Aesthetic Advantage: Studyhttps://practicaldermatology.com/news/hydrocolloid-dressings-after-mohs-surgery-yield-no-aesthetic-advantage-study/2484049/Hydrocolloid dressings (HCDs) and daily petroleum ointment following excisional dermatologic surgery did not perform differently in terms of scar appearance or surgical complications, according to a new trial. The randomized,
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.
- Analysis: Drug Class Influences Clinical Management of Eruptive Keratoacanthoma/Squamous Cell Carcinomahttps://practicaldermatology.com/news/drug-class-influences-clinical-profile-and-management-of-eruptive-kascc/2474440/The clinical features and management of drug-induced eruptive keratoacanthoma (KA) and squamous cell carcinoma (SCC) differ significantly depending on the causative drug class, according to a new analysis of 172 reported cases.
- 2-Year Data: Bimekizumab Can Eliminate Draining Tunnels in HShttps://practicaldermatology.com/news/2-Year-Data-Bimekizumab-Can-Eliminate-Draining-Tunnels-HS/2471535/Two-year data from the BE HEARD trials for bimekizumab-bkzx (BIMZELX®) in moderate-to-severe hidradenitis suppurativa (HS) continued to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by drai
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- AD Drugs Market Predicted to Grow From $10.5 Billion to $24.5 Billionhttps://practicaldermatology.com/news/ad-drugs-market-predicted-grow-105-billion-245-billion/2468511/A new market research report predicts that the global atopic dermatitis (AD) drugs market will grow at a compound annual growth rate of 9.1% from now through 2033, going from $10.5 billion in 2023 to $24.5 billion by 2033. The report, from market.us, is titled, “Atopic Dermatitis Drugs Mar
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter